Skip to main content

Table 1 Clinical characteristics and administration of chemotherapy in 253 patients with primary resection for colorectal liver metastases

From: Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival

Variable, statistics Estimate
Age in years, median (range) 66.1 (22.8, 89.2)
Gender male/female ratio 133/120
Synchronous metastasesa, n (%) 115 (45.5)
Disease-free intervalb in months, median (range) 4 (-14,131)
Resections, n 253
   Hemihepatectomy/lobectomy, n (%) 117 (46.2)
   Wedge/segment resections, n (%) 136 (53.8)
   Simultaneous radiofrequency ablation, n (%) 12 (4.7)
   Two-stage resections, n (%) 3 (1.2)
   Simultaneous colorectal cancer surgery, n (%) 14 (5.5)
Extent of resection margin in mm, median (range) 4 (0-50)
Number of metastases, median (range) 2 (1, 12)
Metastases diameter in cm, median (range) 3.0 (0.2,15.0)
Bilobar metastases, n (%) 94 (37.2)
Number of resections/patient (1/2/3/4/5) 203/36/11/2/1
In-hospital mortality, n (%) 4 (1.6)
Follow-up survivors in years, median (range) 4.7 (1.9-12.9)
Chemotherapy preoperatively, n (%) 88 (34.8)
   Downstaging, n (%) 40 (15.8)
   Perioperativec, n (%) 43 (17.0)
   Adjuvant after colon surgery, n (%) 5 (2.0)
Type of chemotherapy  
   FOLFOXd, n (%) 71 (81.6)
   FOLFIRIe/+bevacizumab, n (%) 8/3 (9.1/3.4)
   FOLFIRI + cetuximab, n (%) 1 (1.1)
   FLVf, n (%) 3 (3.4)
   Other combinations, n (%) 5 (5.7)
Outcome of chemotherapyg (RECIST)  
   Partial response, n (%) 52 (59.1)
   Stable disease, n (%) 32 (36.4)
   Progression, n (%) 2 (2.3)
   Unknown, n (%) 2 (2.3)
Number of cycles  
   ≤3 11 (12.5)
   4-6 40 (45.4)
   7-12 27 (30.7)
   >12 7 (8.0)
   Unknown 3 (3.4)
Chemotherapy adjuvant, n (%) 44 (17.4)
   After neoadjuvant, n (%) 30 (11.9)
   After downstaging, n (%) 7 (2.8)
   Without preoperative chemotherapy, n (%) 7 (2.8)
  1. aSynchronous metastases: detected <1 month after surgery of primary colorectal tumor; bdisease-free interval: time from resection of primary colorectal tumor to detection of hepatic metastases; call patients were offered the FOLFOX regimen; dFOLFOX (oxaliplatin, 5-fluorouracil, leukovorin); eFOLFIRI (irinotecan, 5-fluorouracil, leukovorin); fFLV (5-fluorouracil, leukovorin); gRECIST-criteria measured by computed tomography scan.